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Abstract
 
Using current diagnostic criteria, primary mediastinal B cell lymphoma (PMBL) cannot be distinguished from other types
of diffuse large B cell lymphoma (DLBCL) reliably. We used gene expression profiling to develop a more precise molecular
diagnosis of PMBL. PMBL patients were considerably younger than other DLBCL patients, and their lymphomas fre-
quently involved other thoracic structures but not extrathoracic sites typical of other DLBCLs. PMBL patients had a relatively
favorable clinical outcome, with a 5-yr survival rate of 64% compared with 46% for other DLBCL patients. Gene expression
profiling strongly supported a relationship between PMBL and Hodgkin lymphoma: over one third of the genes that were
more highly expressed in PMBL than in other DLBCLs were also characteristically expressed in Hodgkin lymphoma cells.
 
PDL2
 
, which encodes a regulator of T cell activation, was the gene that best discriminated PMBL from other DLBCLs and
was also highly expressed in Hodgkin lymphoma cells. The genomic loci for 
 
PDL2
 
 and several neighboring genes were
amplified in over half of the PMBLs and in Hodgkin lymphoma cell lines. The molecular diagnosis of PMBL should signifi-
cantly aid in the development of therapies tailored to this clinically and pathogenetically distinctive subgroup of DLBCL.
Key words: gene expression proﬁling • microarray • outcome prediction • PMBL • DLBCL
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Abbreviations used in this paper:
 
 ABC, activated B cell; DLBCL, diffuse large B cell lymphoma; GCB, germinal center B cell; HRS, Hodgkin Reed-
Sternberg; PMBL, primary mediastinal B cell lymphoma.T
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Introduction
 
Primary mediastinal B cell lymphoma (PMBL) has been
recognized as a subtype of diffuse large B cell lymphoma
(DLBCL) based on its distinctive clinical and morphologi-
cal features (1). In many patients given this diagnosis, the
only site of lymphoma involvement is the mediastinum,
but the lymphoma can extend locally to involve other tho-
racic structures and occasionally disseminate to distinctive
extranodal sites such as the kidney and the brain (2). PMBL
patients tend to be young, with a median age of 30–35 yr at
diagnosis, which contrasts with other DLBCL patients who
have a median age of 
 
 
 
60 yr at diagnosis. Pathologically,
PMBL tumors are frequently highly sclerotic and are char-
acterized by a diffuse proliferation of large cells, often with
a clear cytoplasm.
Immunohistochemical analysis has confirmed the B cell
origin of this lymphoma, although the expression of immu-
noglobulin genes is notably low (1). The relationship of
PMBL to other DLBCL subgroups is uncertain. One DL-
BCL subgroup, termed germinal center B cell (GCB)–like
DLBCL, maintains the gene expression program of normal
germinal center B cells, whereas another DLBCL sub-
group, termed activated B cell (ABC)–like DLBCL, ex-
presses genes characteristic of activated B cells and plasma
cells (3–5). PMBLs have low expression of CD10, a marker
of the germinal center stage of B cell differentiation,
prompting speculation that PMBL may be distinct from the
GCB DLBCL subgroup (1).
Comparative genomic hybridization and fluorescence in
situ hybridization analyses have supported the notion that
PMBL is a pathogenetically distinct subgroup of DLBCL.
Gains of chromosome arm 9p have been detected in over
half of the PMBL cases, and this karyotypic abnormality is
only occasionally detected in other DLBCLs (6, 7). Chro-
mosome 9p gains can also be accompanied by amplification
of the 
 
JAK2
 
 gene, and interestingly, both 9p gains and
 
JAK2
 
 amplification have also been detected in Hodgkin
lymphoma (8). Some patients with Hodgkin lymphoma
have been noted to develop PMBL within 1 yr after treat-
ment, and some “grey zone” lymphomas can have histo-
logical features that are intermediate between Hodgkin
lymphoma and PMBL (9, 10). These observations have led
to speculation that PMBL and Hodgkin lymphoma may be
pathogenetically related (1, 11).
Clinically, PMBL is an aggressive lymphoma, and its rel-
ative responsiveness to treatment is controversial (1). Some
studies concluded that PMBL patients have a relatively
poor prognosis (12, 13), but another study showed a 5-yr
overall survival rate of 46% with anthracycline-based che-
motherapy, similar to that of other DLBCLs (14). A more
recent study that combined chemotherapy with radiother-
apy reported an 82% overall survival at 3 yr, a rate much
higher than in other DLBCLs (15).
Imprecision in the diagnosis of PMBL may account for
some of the heterogeneity in reported clinical responses. In
particular, other DLBCLs that may originate by chance in the
mediastinal region may be confused with PMBL. Currently,
 
no molecular tests are routinely available for the diagnosis of
PMBL. Two genes, 
 
MAL
 
 and 
 
FIG1
 
, are expressed frequently
in PMBLs, but these markers may not identify all PMBL
cases, and 
 
FIG1
 
 is also expressed in some DLBCLs (16, 17).
We undertook a gene expression profiling study of
PMBL to establish a molecular diagnosis of this disease. We
identified a gene expression signature of PMBL that distin-
guished this subgroup from other DLBCLs and showed
that PMBL patients have distinctive clinical features and a
favorable overall survival rate after therapy. The PMBL sig-
nature genes revealed an extraordinarily robust gene ex-
pression relationship between PMBL and Hodgkin lym-
phoma, strongly supporting a pathogenetic relationship
between these two lymphoma types.
 
Materials and Methods
 
Analysis of Gene Expression and Clinical Data.
 
Pretreatment
lymphoma biopsy samples were studied according to a protocol
approved by the NCI Institutional Review Board. Lymphoma
biopsies were reviewed by a panel of hematopathologists and
were found to be DLBCLs morphologically. A “training” set of
cases consisted of 36 biopsy specimens from 35 patients for whom
the diagnosis of PMBL was considered. These patients all had
mediastinal masses of at least 6 cm at presentation. These samples
were profiled for gene expression using Lymphochip DNA mi-
croarrays comprised of 15,133 cDNA elements as described (3),
and the data are available at http://llmpp.nih.gov/PMBL. A “val-
idation” set of 274 lymphoma samples was previously profiled us-
ing Lymphochip DNA microarrays comprised of 12,196 cDNA
elements (4); data for these samples were obtained from http://
llmpp.nih.gov/DLBCL. All patients were treated with anthra-
cycline-containing multiagent chemotherapy protocols with
some patients additionally receiving radiation therapy.
The Bayesian statistical procedure used to create the gene ex-
pression-based PMBL predictor has been described (5). In the
training set of cases, a Bayesian PMBL predictor was constructed
from the 46 genes shown in Fig. 2 A. Since cases in the validation
set were profiled on Lymphochip microarrays that lacked some of
these genes, we constructed another Bayesian PMBL predictor us-
ing the 26 discriminating genes that were represented on these mi-
croarrays. After demonstrating that this predictor performed identi-
cally to the 46-gene predictor on the training set (not shown), it
was then used to classify cases in the validation set of cases without
reoptimization of the model parameters (Fig. 2 B).
Survival probabilities were estimated using the Kaplan-Meier
method. P values for survival differences were evaluated using a
log-rank test. P values for differences in age group and gender were
generated using a chi-squared test. P values for differences in age as
a continuous variable were computed using an ANOVA test.
 
Genomic Copy Number Analysis.
 
Quantitative PCR assays
were used to assess the genomic copy number of the 
 
PDL2
 
 gene
relative to the control 
 
PRKCQ
 
 gene, as described (18). Control
samples of genomic DNA from peripheral blood mononuclear
cells of normal volunteers yielded a 
 
PDL2
 
 to 
 
PRKCQ
 
 ratio of 0.99
with a SD of 0.08. A threshold 
 
PDL2 
 
to 
 
PRKCQ
 
 ratio for gain/
amplification of the 
 
PDL2
 
 genomic locus was set at 1.31, which is
four SDs above the mean. A biopsy specimen comprised of 100%
malignant cells would be expected to yield a 
 
PDL2
 
/
 
PRKCQ
 
 ratio
of 1.5 if the malignant cells had a gain of a single chromosomeT
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copy. In some of the DLBCL tumor biopsies studied, up to 40% of
the cells were reactive normal cells; in such biopsies, a gain of a sin-
gle chromosome copy in the malignant cells would yield a 
 
PDL2
 
to 
 
PRKCQ
 
 ratio of 1.30. PCR primers for 
 
PDL2
 
 amplification
were 5
 
 
 
-CTGGCCAAACGTCAGCGT-3
 
 
 
 and 5
 
 
 
-TGACCTG-
GTAGAGGCCTTCAG-3
 
 
 
, and the fluorescent Taqman probe
was 5
 
 
 
-CCTGCCAACACCAGCCACTCCAG-3
 
 
 
. PCR prim-
ers for 
 
PRKCQ
 
 amplification were 5
 
 
 
-TCGCCATTTCTTCG-
GATTG-3
 
 
 
 and 5
 
 
 
-GCCTCGCCCTGACAAGACT-3
 
 
 
, and the
fluorescent Taqman probe was 5
 
 
 
-TGTCCAACTTTGACT-
GCGGGTCCTG-3
 
 
 
. 
 
JAK2
 
 and 
 
SMARCA2
 
 genomic copy num-
bers were assessed relative to the 
 
CDKN2C
 
 gene. In control pe-
ripheral blood mononuclear cell samples, the 
 
JAK2 
 
to 
 
CDKN2C
 
ratio was 0.91 
 
 
 
 0.08, and the 
 
SMARCA2 
 
to 
 
CDKN2C
 
 ratio was
0.99 
 
 
 
 0.13. PCR primers for 
 
JAK2
 
 amplification were 5
 
 
 
-GTC-
CTAATGATCTCTTAGCTAGGATGTG-3
 
 
 
 and 5
 
 
 
-AATAT-
GCTCATGATCCCAGATTTTC-3
 
 
 
, and the fluorescent Taq-
man probe was 5
 
 
 
-TTTATGTTGACAACAGATTTGAAT-
AACTCGAGCAAA-3
 
 
 
. PCR primers for SMARCA2 amplifi-
cation were 5 -CGAGTTTTGCCTTGTGGACTG-3  and 5 -
CCTTATCCCCTTTGGGTTAGTGA-3 , and the fluorescent
Taqman probe was 5 -AAGGTTCAAGTTTGCTAGTCCG-
CAGATTGC-3 . PCR primers for CDKN2C amplification
were 5 -TCAGGAGTCGGGAGGAATAAAA-3  and 5 -CGG-
CATGACCGTAGAGACAA-3 , and the fluorescent Taqman
probe was 5 -AATTTTCTAATCAGAGCTCAGCTGCAGT-
GTC-3 .
Expression of PMBL Signature Genes in Primary Hodgkin Reed-
Sternberg Cells. A case of nodular sclerosis classical Hodgkin
lymphoma with easily recognizable Hodgkin Reed-Sternberg
(HRS) cells was identified and 4- m sections were cut from the
frozen tissue block embedded in OCT and applied to plastic
film–coated slides (Leica). The section was briefly stained in
freshly prepared hematoxylin and eosin after fixation in 70% ethyl
alcohol. Microdissection was performed using a Leica AS LMD.
The cutting nitrogen laser used in this microdissection method
destroyed reactive cells that surrounded the HRS cells. About 700
HRS cells were dissected from the tissue sections and collected in
400  l of Trizol reagent (Invitrogen). An equivalent number of
cells from the Hodgkin cell line L428, the PMBL cell line K1106,
and the GCB DLBCL cell line OCI-Ly19 was also collected in
Trizol. RNA was precipitated from each sample and resuspended
in 190  l of DEPC-treated water. A 5- l aliquot of RNA was
used in a Taqman one-step quantitative RT-PCR assay per-
formed according to the manufacturer’s protocol (Applied Bio-
systems) using Assays-on-Demand reagents for the following
genes:  CCL17/TARC (Hs00171074), SNFT (Hs00232744),
MAL (Hs00242749), and TNFRSF6/Fas (Hs00236330) relative
to ACTB/ -actin (Hs99999903_m1). Immunoperoxidase staining
for MAL protein in a case of classical Hodgkin lymphoma was
performed as described (16).
Online Supplemental Material. Fig. S1 shows the expression of
“lymph node” signature genes in PMBLs, and Fig. S2 shows the
expression of PMBL signature genes in Hodgkin lymphoma cell
lines. Figs. S1 and S2 are available at http://www.jem.org/cgi/
content/full/jem.20031074/DC1.
Results
Development of a PMBL Predictor. To discover a gene ex-
pression signature of PMBL, we first identified 35 DLBCL pa-
tients whose lymphomas involved the mediastinum promi-
nently and for whom the diagnosis of PMBL was
entertained. Since the clinical diagnosis of PMBL is impre-
cise, we anticipated that this group of patients would be het-
erogeneous, including some cases of “true” PMBL and
other cases with standard DLBCL that happened to involve
the mediastinum. We used Lymphochip DNA microarrays
to profile gene expression in tumor biopsies from these pa-
tients and in 25 biopsies from patients with DLBCL who
had previously been assigned to either the ABC or GCB
subgroup (4). A hierarchical clustering algorithm (19) was
used to organize the genes by their expression patterns across
these lymphoma samples. We noted a large group of genes
that were tightly clustered together in the resulting dendro-
gram and that were more highly expressed in the lympho-
mas with mediastinal involvement than in the other DLB-
CLs (Fig. 1 A). This gene cluster included two genes that
had previously been shown to be highly expressed in PMBL
cases, MAL and FIG1 (16, 17), along with many other genes
that had not previously been associated with PMBL.
Some of the lymphomas with mediastinal involvement
did not express this set of putative PMBL signature genes,
and we suspected that these cases were more likely to be
conventional DLBCLs than PMBL. We used hierarchical
clustering to organize the cases according to their expres-
sion of the PMBL signature genes, which resulted in two
major clusters of cases (Fig. 1 B). One cluster contained 21
samples that were designated as “PMBL core” samples by
virtue of their high expression of PMBL signature genes.
The other cluster contained some samples that had virtually
no expression of these genes and other samples that did ex-
press these genes, albeit at lower levels than in the PMBL
core cases.
We next developed a gene expression-based method to
distinguish the PMBL core cases from the GCB and ABC
DLBCL cases. This PMBL predictor used a Bayesian algo-
rithm to assign a probability that an individual case be-
longed to the PMBL core group versus the DLBCL group
(5). Briefly, this algorithm begins with the selection of a set
of differentially expressed genes between two cancer
groups, A and B. For each biopsy sample, the expression
levels of these genes are combined linearly to derive a sin-
gle “linear predictor score.” Each cancer group will have a
different distribution of linear predictor scores. Based on
these distributions, Bayes rule can be used to estimate the
probability that a particular sample belongs to cancer group
A or cancer group B. An arbitrary probability cutoff of
 90% is used to classify a sample into a cancer group.
Given the heterogeneity of DLBCL, it was challenging to
select an optimal set of differentially expressed genes to be
used in the PMBL predictor. As a first step, we chose genes
that were differentially expressed between the PMBL core
group and both the GCB and ABC DLBCL subgroups
(P   0.001). This set of genes included all of the PMBL signa-
ture genes that had been identified by hierarchical clustering
(Fig. 1 A) and a large number of additional genes. Many of
the genes in this set belonged to the so-called “lymph node”
gene expression signature, which was previously identifiedT
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as a variable feature of DLBCL tumors that appears to reflect
a host response to the malignant cells (3, 4). The lymph
node signature includes genes encoding extracellular matrix
components and genes that are characteristically expressed
in macrophage, NK, and T cells. It is well known that
PMBL tumors are often intensely fibrotic (20), and indeed,
Figure 1. Identification of a
PMBL gene expression signature.
(A) Hierarchical clustering iden-
tified a set of 23 PMBL signature
genes that were more highly ex-
pressed in most lymphomas with
a clinical diagnosis of PMBL than
in lymphomas assigned to the
GCB or ABC DLBCL sub-
groups. Each row presents gene
expression measurements from a
single Lymphochip microarray
feature representing the genes
indicated. Each column repre-
sents a single lymphoma biopsy
sample. Relative gene expression
is depicted according to the color
scale shown. (B) Hierarchical
clustering of the lymphoma bi-
opsy samples based on expression
of the PMBL signature genes
identified in A. A “core” cluster
of lymphoma cases was identified
that highly expressed the PMBL
signature genes.T
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most of the biopsy samples in the PMBL core group
had high expression of the lymph node signature genes
(Fig.  S1, available at http://www.jem.org/cgi/content/
full/jem.20031074/DC1). We chose to exclude these genes
from our PMBL predictor since they might cause some
DLBCLs with high expression of the lymph node signature
Figure 2. Development of a gene expression-based
molecular diagnosis of PMBL. (A) A PMBL predictor was
created based on the expression of the 46 genes shown.
Relative gene expression for each lymphoma biopsy sample
is presented according to the color scale shown in Fig. 1.
The probability that each sample is PMBL or DLBCL
based on gene expression is shown at the top. See Results
for details. (B) Validation of the PMBL predictor. The
PMBL predictor was used to classify 274 lymphoma samples from an independent cohort of patients (4) as PMBL or DLBCL. Some patients had been
diagnosed as PMBL based on current diagnostic criteria (PMBL clinical diagnosis), whereas others had not been given this diagnosis (DLBCL clinical
diagnosis). The prediction results are summarized on the right, and the relative gene expression for each case that was classified by the predictor as PMBL
is shown on the left. In addition, the average expression of each gene in the samples classified as DLBCL is shown. Shown are the 20 genes from the
PMBL predictor (A) that were more highly expressed in PMBL than in DLBCL and that were represented on the Lymphochip microarrays used to
profile this set of lymphoma samples (4). Not shown are eight genes from the PMBL predictor that were more highly expressed in DLBCL than in PMBL.T
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Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma 856
genes to be misclassified as PMBLs. Therefore, we refined
our list of PMBL distinction genes by requiring that they
also be differentially expressed between the PMBL core
group and subgroup of six DLBCLs with high expression of
the lymph node signature genes (P   0.001).
The resulting list of PMBL/DLBCL distinction genes was
used to create a PMBL predictor, which included 35 genes
that were more highly expressed in PMBL and 11 genes that
were more highly expressed in DLBCL (Fig. 2 A). All of the
PMBL core samples were classified as PMBL according to
this predictor as were six of the other lymphomas with me-
diastinal involvement. However, nine of the lymphomas
with mediastinal involvement were classified as DLBCL by
the predictor, as were all of the GCB and ABC DLBCLs.
We next tested the performance of the PMBL predictor
on an independent set of 274 DLBCL cases that we had
previously analyzed by gene expression profiling (4). In this
validation set, 11 cases were identified on clinical grounds
as being consistent with a diagnosis of PMBL, and the
PMBL predictor classified 9 of these as PMBL (Fig. 2 B).
Interestingly, 12 of the remaining 263 DLBCL samples
were classified as PMBL by the predictor. Fig. 2 B shows
that these cases were indistinguishable by gene expression
from the 9 cases given a diagnosis of PMBL on clinical
grounds. As expected, the average expression of the PMBL
predictor genes in the 249 samples classified as DLBCL was
notably lower than in the 22 PMBL cases (Fig. 2 B). Thus,
PMBL represents a third subgroup of DLBCL that can be
distinguished by gene expression profiling from GCB DL-
BCL and ABC DLBCL.
Previously, we developed a Bayesian predictor of the
distinction between the ABC and GCB DLBCL subgroups
(21). Of the 48 cases assigned to the PMBL subgroup, this
ABC/GCB predictor classified 42 as GCB DLBCL and
none as ABC DLBCL, whereas 8 cases remained unclassi-
fied. Although the PMBL subgroup was somewhat more
related to the GCB subgroup than the ABC subgroup, the
GCB and PMBL subgroups were easily distinguishable us-
ing the PMBL predictor.
The PMBL Subgroup Is Clinically Distinct from Other DL-
BCL Subgroups. Table I compares the clinical parameters
of patients assigned to the PMBL, ABC, and GCB sub-
groups of DLBCL by our gene expression-based predictor.
PMBL patients were significantly younger than other DL-
BCL patients, with a median age at diagnosis of 33 yr com-
pared with 66 and 61 yr for ABC and GCB DLBCL
patients, respectively. Although there was no significant
difference in the gender distributions among the DLBCL
subgroups, young women (age  35 yr) accounted for 35%
of the PMBL patients, which was significantly higher than
in the other DLBCL subgroups. Young men (age  35 yr)
were also more frequently represented in the PMBL sub-
group, accounting for 19% of the patients. Correspond-
ingly, older men and women (age  60) were significantly
underrepresented in the PMBL subgroup. These clinical
characteristics were observed in both the training and vali-
dation sets of PMBL cases, demonstrating that the PMBL
predictor reproducibly identified a clinically distinct sub-
group of DLBCL patients.
The PMBL subgroup defined by the PMBL predictor
had a relatively favorable overall survival rate after therapy
(Fig. 3 A). PMBL patients had a 5-yr survival rate of 64%,
which was superior to the rate of 46% for all DLBCL pa-
tients (P   0.0067). The survival of the PMBL subgroup
was significantly better than the 30% 5-yr survival rate of
the ABC DLBCL subgroup (Fig. 3 A; P   5.8 E-5), but
Table I. Clinical Characeristics of PMBL and Other DLBCL Patients
PMBL PMBL PMBL
ABC DLBCL
(n   86)
GCB DLBCL
(n   103)
Training set
(n   18)
Validation set
(n   25)
 All cases
(n   43) P value
Median age 66 61 33 33 33 4.4E-16
Age  35 5% 10% 52% 56% 53% 7.2E-14
Age 35–60 29% 38% 44% 28% 37%
Age  60 66% 52% 4% 17% 9%
Gender   male 59% 53% 44% 50% 47% 0.38
Female  35 2% 3% 32% 39% 35% 1.1E-12
Male  35 2% 7% 20% 17% 19%
Female 35–60 6% 18% 24% 6% 16%
Male 35–60 23% 19% 20% 22% 21%
Female  60 33% 25% 0% 6% 2%
Male  60 34% 27% 4% 11% 7%T
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only marginally better than the 59% 5-yr survival rate of
the GCB DLBCL subgroup (P   0.18). In our series, 14
PMBL patients received radiation therapy in addition to
multiagent chemotherapy, but their survival was not signif-
icantly different from those that did not (not shown). No-
tably, no patients in the PMBL subgroup died after 37 mo,
suggesting that those PMBL patients who survive more
than 3 yr have a high probability of being cured by multi-
agent chemotherapy.
Finally, the lymphomas of PMBL patients characteristi-
cally involved other thoracic structures in addition to the
mediastinum (Fig. 3 B). Lung, pleura, pericardium, and
breast were more frequently involved in PMBL than in
other DLBCLs. Conversely, the gastrointestinal tract, bone
marrow, liver, and muscle were more frequently involved
in other DLBCLs than in PMBLs. This distinctive tissue
distribution of the PMBLs further supports their classifica-
tion as a separate DLBCL subgroup.
Chromosome 9p Aberrations in PMBL. Previous studies
demonstrated that gains of chromosome arm 9p are fre-
quent in PMBL, and one case of PMBL was found to have
a high level amplification of the JAK2 gene, which resides
at chromosome band 9p24 (6–8). We noted that JAK2 and
three other genes located near JAK2 on chromosome band
9p24 (PDL1, PDL2, and SMARCA2) were all expressed at
significantly higher levels in PMBLs than in other DLBCLs
(Figs. 1 and 2). Indeed, PDL2 was the overall best PMBL
distinction gene represented on the microarray, with a 5.6-
fold higher expression, on average, in PMBLs than in other
DLBCLs (P   7.55 E-15) (Fig. 2 A).
To directly assess chromosome 9p gains and amplifica-
tions in our set of PMBLs, we designed a quantitative PCR
assay for PDL2 in which the genomic copy number of this
gene was compared with that of a control gene on chro-
mosome band 10p15 (PRKCQ). Using control genomic
DNA from peripheral blood mononuclear cells of 10 nor-
Figure 3. Clinical characteristics of PMBL patients. (A) Kaplan-Meier plot of overall survival of PMBL, GCB DLBCL, and ABC DLBCL patients after
chemotherapy. (B) Distribution of extranodal sites of disease involvement at diagnosis for PMBL and other DLBCL patients.
Figure 4. Amplification of genes on chromosome band 9p24 in PMBL. (A) The genomic copy number of the PDL2 gene on chromosome arm 9p is
compared with that of the control PRKCQ gene. A PDL2 to PRKCQ ratio above the threshold indicated by the dashed line was taken as evidence of a
gain/amplification of the PDL2 genomic locus (see Materials and Methods for details). HL, Hodgkin lymphoma cell lines L428, HDLM2, and L540.
Normal control is defined as peripheral blood mononuclear cell samples from normal volunteers. (B) Coamplification of the PDL2,  JAK2, and
SMARCA2 genes in PMBL. The genomic copy numbers of the JAK2 and SMARCA2 genes relative to the control CDKN2C gene are shown for seven
PMBL cases with greater than twofold amplification of PDL2 (A) and for three normal control samples. The structure of the chromosome 9p24 region
near the PDL2 gene is shown. cen, centromere; tel, telomere.T
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Figure 5. Relationship of PMBL to Hodgkin lymphoma.
Relative gene expression is shown in primary PMBLs (average
of all biopsy samples), the PMBL cell line K1106, three
Hodgkin lymphoma (HL) cell lines, and six GCB DLBCL cell
lines, according to the color scale shown in Fig. 1. (A) PMBL
signature genes that are also expressed at high levels in
Hodgkin lymphoma cell lines compared with GCB DLBCL
cell lines. (B) PMBL signature genes not expressed in Hodgkin
lymphoma cell lines. (C) Mature B cell markers expressed in
PMBL and GCB DLBCL but not in Hodgkin lymphoma.
(D) Enrichment within the set of PMBL signature genes of
genes highly expressed in Hodgkin lymphoma cell lines or in
the K1106 PMBL cell line relative to GCB DLBCL cell lines.
See Results for details.T
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mal donors, the average PDL2 to PRKCQ ratio was 0.99,
as expected (Fig. 4 A). More than half of the PMBLs tested
(30 out of 48; 62.5%) had elevated PDL2 to PRKCQ ratios
(see Materials and Methods), consistent with a chromo-
some 9p gain and/or amplification of the PDL2 locus. By
contrast, only 1 out of 23 DLBCL samples had a similarly
elevated  PDL2  to  PRKCQ ratio. Seven of the PMBLs
(23%) had PDL2 to PRKCQ ratios in excess of two, con-
sistent with an amplification of the PDL2 locus. Quantita-
tive PCR assays for the JAK2 and SMARCA2 genes de-
tected coamplification of these genes in the seven cases
with a twofold PDL2 amplification (Fig. 4 B), and no
PMBL cases were found with only amplification of the
JAK2 gene (not shown). The preferential gain/amplifica-
tion of this chromosomal region in PMBL underscores the
unique pathogenesis of this DLBCL subgroup.
Similarities Between PMBL and Hodgkin Lymphoma. Two
of the PMBL distinction genes, CD30 and TARC, are
both characteristically expressed in the malignant HRS cells
of Hodgkin lymphoma (22, 23). This led us to investigate
whether other PMBL distinction genes might be expressed
in Hodgkin lymphoma. Given the rarity of HRS cells in
primary Hodgkin lymphoma biopsies, we addressed this ques-
tion by profiling gene expression in three cell lines derived
from Hodgkin lymphoma, L428, HDLM2, and L540. Pre-
vious gene expression profiling studies of Hodgkin lym-
phoma cell lines (including L428 and HDLM2) have dem-
onstrated that they reflect the gene expression program of
primary HRS cells (24). For comparison, we profiled gene
expression in one cell line derived from PMBL, K1106
(25), and six DLBCL cell lines that resemble the GCB
DLBCL subgroup in gene expression.
For this analysis, we selected a set of PMBL signature
genes that were more highly expressed in primary PMBL
than in other DLBCLs (P   0.001). A set of Hodgkin lym-
phoma signature genes was chosen such that at least two of
the Hodgkin lymphoma cell lines had more than twofold
greater expression than the average expression in the GCB
DLBCL cell lines. Of the 348 PMBL signature genes, a re-
markably large subset of 118 (34%) were also Hodgkin
lymphoma signature genes (Fig. 5 A). Since Hodgkin lym-
phoma signature genes represented only 13% of all Lym-
phochip microarray genes, the set of PMBL signature genes
were 2.6-fold enriched in Hodgkin lymphoma signature
genes (Fig. 5 D). For comparison, we identified a set of
genes that were more highly expressed (greater than or
equal to twofold) in the PMBL cell line K1106 than in the
GCB DLBCL cell lines and found that 153 of these genes
were also PMBL signature genes. This represents a 2.75-
fold enrichment of K1106 high genes within the set of
PMBL signature genes, which is similar to the enrichment
of Hodgkin lymphoma signature genes (Fig. 5 D). Of the
118 genes that were both PMBL and Hodgkin lymphoma
signature genes, 69% were also more highly expressed in
Hodgkin lymphoma cell lines than in two ABC DLBCL
cell lines, OCI-Ly3 and OCI-Ly10, demonstrating that
these genes also distinguish PMBL and Hodgkin lym-
phoma from ABC DLBCL. Recently, gene expression data
from four Hodgkin lymphoma cell lines and five GCB DL-
BCL cell lines were generated using Affymetrix microar-
rays (24). Of the 235 PMBL signature genes represented on
these arrays, 86 (37%) were twofold more highly expressed
in greater than or equal to three Hodgkin lymphoma cell
lines than in the GCB DLBCL cell lines (Fig. S2, available
at http://www.jem.org/cgi/content/full/jem.20031074/
DC1), confirming the gene expression relationship be-
tween PMBL and Hodgkin lymphoma.
Notably, two of the previously described PMBL signa-
ture genes, MAL and FIG1, were also highly expressed in
Hodgkin lymphoma cell lines. In addition, a number of
cytokines (IL-15, CSF-1, and TRAIL) and chemokines
(TARC, RANTES, and Fractalkine) were also expressed
by both PMBL and Hodgkin lymphoma cell lines. Many of
the genes in this list are inducible by various stimuli, in-
cluding interferon-responsive genes (STAT1, GBP1, IFP35,
AIM2, IFIT2, IFI-6–16, PML, and IRF-1) and targets of
Figure 6. Expression of PMBL signature genes in primary HRS cells. (A) Quantitative RT-PCR measurement of mRNA levels for CCL17/TARC,
SNFT, MAL, and TNFRSF6/Fas in the indicated cell types. mRNA expression for each gene is presented relative to the expression of ACTB/ -actin.
(B) Immunohistochemical staining of MAL protein in a malignant HRS cell from a case of nodular sclerosis classical Hodgkin lymphoma.T
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the NF- B transcription factor (A20, jun-B, I B , NF B2,
TRAF1, IL-15, CSF-1, and RANTES), possibly indicating
that PMBL and Hodgkin lymphoma have activated a simi-
lar set of signaling pathways.
We confirmed the expression of four PMBL signature
genes in primary HRS cells that we microdissected from a
case of classical Hodgkin lymphoma (Fig. 6 A). Using
quantitative RT-PCR assays, CCL17/TARC,  SNFT,
MAL, and TNFRSF6/Fas were all found to be expressed as
mRNA in primary HRS cells at levels comparable to those
observed in the L428 Hodgkin lymphoma cell line and the
K1106 PMBL cell line. By contrast, the GCB DLBCL cell
line OCI-Ly19 did not detectably express these PMBL sig-
nature genes. In addition, using immunohistochemistry, we
could detect MAL protein expression in primary HRS cells
of some cases of classical Hodgkin lymphoma (Fig. 6 B).
Using the quantitative PCR assay for PDL2 genomic al-
terations, all three Hodgkin lymphoma cell lines had
PDL2 to PRKCQ ratios above two (Fig. 4 A). This result
is in keeping with previous reports of chromosome 9p24
gains and amplification in Hodgkin lymphoma (8) and
provides a further connection between PMBL and
Hodgkin lymphoma.
Despite these links between PMBL and Hodgkin lym-
phoma, these two lymphoma types were clearly distin-
guishable by the expression of other genes. A subset of
PMBL signature genes were highly expressed in the K1106
PMBL cell line but not in the Hodgkin lymphoma or GCB
DLBCL cell lines (Fig. 5 B). Another clear difference be-
tween PMBL and Hodgkin lymphoma was in the expres-
sion of mature B cell genes. Hodgkin lymphoma cells ex-
tinguish expression of much of the mature B cell gene
expression program by an unknown mechanism (24). Ac-
cordingly, several mature B cell genes (CD19, CD20,
CD22, CD79A, CD79B, and Oct-2) were not detectably
expressed in the Hodgkin lymphoma cell lines, whereas
these genes were expressed in PMBLs and in GCB DLBCLs
(Fig. 5 C). Thus, PMBL shares some, but not all, of the
Hodgkin lymphoma gene expression program.
Discussion
We have used gene expression profiling to establish a
molecular diagnosis of PMBL. The lymphoma cases identi-
fied by our predictor as PMBL have several clinical and
molecular features in common with PMBL cases identified
by current diagnostic methods (1). First, 53% of the pa-
tients predicted to be PMBL were younger than 35 at diag-
nosis, and in this age group women outnumbered men 1.8
to 1. Second, the lymphomas of these PMBL patients fre-
quently extended to other thoracic structures besides the
mediastinum but did not involve many of the extrathoracic
sites typical of other DLBCL subgroups. Third, two of the
molecular markers previously associated with PMBL, MAL
(16), and FIG1 (17) were expressed in the majority of
PMBL cases identified by our predictor. Finally, over half
of the PMBLs identified by our predictor had a gain/ampli-
fication of a region of chromosome 9p24, which is a hall-
mark genomic abnormality of PMBL (6, 7).
We propose that the molecular diagnosis of PMBL by
gene expression yields a more precise definition of this DL-
BCL subgroup than is provided by current diagnostic
methods. Of the 46 patients for whom the diagnosis of
PMBL was considered, 35 (76%) were classified as PMBL
by gene expression. Of the 11 cases that were not classified
as PMBL by our predictor, 7 were classified as GCB DL-
BCL and 4 were classified as ABC DLBCL by gene expres-
sion (unpublished data), which roughly reflects the distri-
bution of these subgroups among all DLBCL cases (4).
Therefore, it appears likely that these cases represent other
forms of DLBCL that happened to predominantly involve
the mediastinum at presentation.
Gene expression profiling identified PMBL as a sub-
group of DLBCL with a relatively favorable survival rate
after therapy: the 5-yr survival rate of PMBL was 64%
compared with 59% and 30% for the GCB and ABC DL-
BCL subgroups, respectively. In our series, four patients
with predominant mediastinal involvement had tumors that
were not classified as PMBL by our predictor but instead
were found to be ABC DLBCL; these patients had rapid
disease progression and died within 2 yr of diagnosis. This
example highlights how molecular diagnosis can provide
valuable prognostic information that could help guide the
management of DLBCL patients with mediastinal masses.
The gene expression signature of PMBL revealed a fasci-
nating relationship between this lymphoma subgroup and
Hodgkin lymphoma. Over one third of all PMBL signature
genes were also more highly expressed in Hodgkin lym-
phoma cell lines than in GCB DLBCL cell lines. Five of
the PMBL signature genes that we identified (MAL,
SNFT, TNFRSF6, TARC, and CD30) have been shown
to be expressed as proteins in primary HRS cells (Fig. 6 and
references [22, 23]). Further, we found that over half of the
PMBLs and three Hodgkin lymphoma cell lines shared
gains/amplifications in a region of chromosome 9p, in ac-
cord with previous studies (6–8). The PMBLs identified in
our study shared many clinical and pathological features
with classical Hodgkin lymphomas, especially those with
nodular sclerosis histology (26). Both lymphoma types are
prevalent in younger patients, especially women, and fre-
quently involve the mediastinum and other thoracic struc-
tures. As the name implies, nodular sclerosis Hodgkin lym-
phomas are characterized by a fibrotic stromal cell reaction,
which is also observed frequently in PMBLs (Fig. S1). Fur-
ther, there are reports of Hodgkin lymphoma patients who
developed PMBL as a second malignancy within one year
after treatment (9, 10). These findings strongly support the
hypothesis that there is a pathogenetic overlap between
PMBL and some forms of Hodgkin lymphoma (1, 11).
Two general possibilities could account for the striking
gene expression similarities between PMBL and Hodgkin
lymphoma. First, the PMBL signature genes that are also
expressed by Hodgkin lymphoma may be the downstream
targets of a signaling pathway or transcription factor that isT
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active in both lymphoma types. Many of these genes are
known to be activated by the NF- B or interferon signal-
ing pathways, but the actual pathways responsible for their
expression in these lymphomas remain to be elucidated. A
second possibility is that PMBL and some forms of
Hodgkin lymphoma may originate from a thymic B cell
(16, 27, 28). Indeed, 60% of Hodgkin lymphomas involve
the mediastinum at presentation and can involve the thy-
mus (29). In this scenario, the gene expression program that
is shared by PMBL and Hodgkin lymphoma might reflect
the normal characteristics of thymic B cells (16, 27, 28) or
might reflect an oncogenic mechanism that is required for a
malignant B cell to develop in this anatomical site.
It is intriguing that the chromosome 9p region that is
gained/amplified in PMBL and Hodgkin lymphoma con-
tains two regulators of T cell responses, PDL1 and PDL2.
These genes encode members of the B7 family that are
ligands for the PD-1 receptor on T cells (30–34) but may
also bind other T cell surface molecules (35). PDL1 and
PDL2 have been reported to have both negative and posi-
tive effects on T cell responses (30–35), which may be ex-
plained by the existence of more than one receptor for
these ligands on T cells (35). Expression of PDL1 on tumor
cells has been shown to inhibit tumor immunity (34, 36),
and therefore PDL1 expression might allow a malignant B
cell arising in the thymus to evade T cell recognition. Al-
ternatively, the ability of PDL2 to costimulate T cells might
lead to local cytokine production that is beneficial to the
tumor cells. It is important to emphasize that PDL1 and
PDL2 were highly expressed in most PMBLs, even those
that lacked evidence of gains or amplifications of this geno-
mic region. Thus, elevated transcription of these genes ap-
pears to be a characteristic feature of PMBL that may be
augmented by genomic copy number gains. Besides PDL1
and PDL2, the amplicon on chromosome 9p in PMBL
includes  JAK2, which encodes a tyrosine kinase, and
SMARCA2, which encodes a putative chromatin regula-
tor. Functional studies will be needed to elucidate the rela-
tive contributions of each of these chromosome 9p genes
to the pathogenesis of PMBL and Hodgkin lymphoma.
Despite these striking parallels between PMBL and
Hodgkin lymphoma, there are important differences. A
subset of the PMBL signature genes was not expressed
highly in Hodgkin lymphoma cell lines, and the down-reg-
ulation of mature B cell genes that is characteristic of
Hodgkin lymphoma was not observed in PMBLs. In addi-
tion, the intense immune cell infiltration that is characteris-
tic of Hodgkin lymphoma is not observed in most PMBLs.
Interestingly, “grey zone” lymphomas have been described
that have histological features of both PMBL and Hodgkin
lymphoma (1, 11). Such cases may indicate that there is a
spectrum of lymphomas between PMBL and Hodgkin
lymphoma, a prospect that can be tested by gene expression
profiling and other molecular analyses.
Finally, our studies emphasize that DLBCL is a hetero-
geneous diagnostic category that harbors at least three mo-
lecularly and clinically distinct subgroups: GCB DLBCL,
ABC DLBCL, and PMBL. Clearly, clinical trials in DL-
BCL must incorporate gene expression profiling so that
these three disease entities can be recognized. The molecu-
lar diagnosis of these DLBCL subgroups is the first step to-
ward understanding the oncogenic mechanisms that cause
these diseases, which will ultimately lead to rational and
disease-specific treatments.
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